EOLS - NASDAQ
Evolus, Inc.
$6.03
-2.3%Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
At a Glance
Live SnapshotEvolus, Inc. Management Team
Ms. Sandra Beaver
Chief Financial Officer
Compensation
$753,208
Ms. Tomoko Yamagishi-Dressler
Chief Marketing Officer
Compensation
$677,374
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.
Chief Medical Officer and Head of Research & Development
Compensation
$811,076
Mr. Jeffrey J. Plumer
General Counsel
Mr. Nareg Sagherian
Head of Global Investor Relations & Corporate Communications
Mr. David Moatazedi
President, Chief Executive Officer & Director
Compensation
$1,671,957
Ms. Jessica Novak
Senior Vice President of Human Resources
Mr. Kurt Knab
Senior Vice President of Sales
Evolus, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.48M and sold $2.21M worth of EOLS shares, resulting in $730K of net selling activity.
3 Months
0
0.00
163.5K
796.93K
-797K
-$797K
3-6 Months
0
0.00
12.8K
91.53K
-92K
-$92K
6-9 Months
143.4K
1.09M
0
0.00
+1.1M
+$1.09M
9-12 Months
50.0K
393.49K
133.6K
1.33M
-933K
-$933K
Top Buyers
Mitchell Tatjana
Officer: Chief Financial Officer
$1.09M
Stewart Brady
Director
$204K
White Albert G Iii
Director
$189K
Top Sellers
Moatazedi David
Director, Officer: See Remarks
$1.99M
Avelar Rui
Officer: See Remarks
$178K
Yamagishi-Dressler Tomoko
Officer: Chief Marketing Officer
$43K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $730K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider buyers and 3 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
EOLS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | May 08, 2023 | June 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 26, 2021 | June 08, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 17, 2020 | May 01, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 10, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.